Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation

BACKGROUND: The silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation occurs frequently in acute myeloid leukemia (AML). This epigenetic alteration can be reversed by 5-aza-2’-deoxcytidine (decitabine, 5-AZA-CdR). Although 5-AZA-CdR can induce complete remissions in patients with AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Momparler, Richard L, Côté, Sylvie, Momparler, Louise F, Idaghdour, Youssef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194463/
https://www.ncbi.nlm.nih.gov/pubmed/25313314
http://dx.doi.org/10.1186/1868-7083-6-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194463/
https://www.ncbi.nlm.nih.gov/pubmed/25313314
http://dx.doi.org/10.1186/1868-7083-6-19

Ejemplares similares